Fate Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Fate Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- FATE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001434316
- EIN
- 65-1311552
Board of directors
-
Bahram Valamehr · Director · President and CEOSince 2025
-
J. Scott Wolchko · Director · President and CEOSince 2023
-
Jeremy Green · DirectorSince 2023
-
John Mendlein · DirectorSince 2023
-
Karin Jooss · DirectorSince 2023
-
Laura Hamill · DirectorSince 2026
-
Matt Abernethy · DirectorSince 2025
-
Michael Stewart Lee · DirectorSince 2023
-
Neelufar Mozaffarian · DirectorSince 2024
-
Robert Hershberg · DirectorSince 2023
-
Robert S. Epstein · DirectorSince 2023
-
Shefali Agarwal · DirectorSince 2023
- Since 2023
-
William H. Rastetter · DirectorSince 2023
-
Yuan Xu · DirectorSince 2023
Chief executives
J. Scott Wolchko
· President and CEO
Dates unknown
Bahram Valamehr
· President and CEO
Dates unknown
Director election results
Annual meeting of June 12, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
97.2%
-
97.7%
-
99.7%
Board connections
8 of this board's directors also sit on 17 other boards.
- via Jeremy Green and Michael Stewart Lee
- via Timothy Coughlin
- via Jeremy Green
- via Robert Hershberg
- via Laura Hamill
- via Jeremy Green
- via William H. Rastetter
- via Robert S. Epstein
- via Laura Hamill
- via William H. Rastetter
- via Robert Hershberg
- via Laura Hamill
- via Timothy Coughlin
- via Robert S. Epstein
- via Timothy Coughlin
- via Yuan Xu
- via Timothy Coughlin
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $322,811
- 6 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 4, 2026 | Bahram Valamehr Director, Officer (President and CEO) | Open-market sale | −43,947 | $2.46 | $108,101 |
| Aug 4, 2026 | TAHL CINDY Officer (See Remarks) | Open-market sale | −38,800 | $2.46 | $95,405 |
| May 20, 2026 | TAHL CINDY Officer (See Remarks) | Open-market sale | −25,590 | $1.88 | $48,109 |
| May 20, 2026 | Bahram Valamehr Director, Officer (President and CEO) | Open-market sale | −28,946 | $1.88 | $54,418 |
| May 6, 2026 | TAHL CINDY Officer (See Remarks) | Option exercise | +122,220 | $1.32 | $161,330 |
| May 6, 2026 | TAHL CINDY Officer (See Remarks) | Option exercise | +44,444 | $1.05 | $46,666 |
| May 5, 2026 | Robert S. Epstein Director | Option exercise | +25,000 | $1.69 | $42,250 |
| May 5, 2026 | William H. Rastetter Director | Option exercise | +25,000 | $1.69 | $42,250 |
| Apr 20, 2026 | Jeremy Green Director, 10% owner | Other | −8,977,624 | — | — |
| Apr 20, 2026 | Jeremy Green Director, 10% owner | Other | +8,977,624 | — | — |
| Jan 15, 2026 | TAHL CINDY Officer (See Remarks) | Grant or award | +100,000 | — | — |
| Jan 15, 2026 | Adawi Kamal Officer (Chief Financial Officer) | Grant or award | +25,000 | — | — |
| Jan 15, 2026 | Bahram Valamehr Director, Officer (President and CEO) | Grant or award | +335,000 | — | — |
| Jan 9, 2026 | TAHL CINDY Officer (See Remarks) | Open-market sale | −10,589 | $1.06 | $11,224 |
| Jan 9, 2026 | Bahram Valamehr Director, Officer (President and CEO) | Open-market sale | −5,190 | $1.07 | $5,553 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.